Article (Scientific journals)
Recommendations for an update of the 2010 European regulatory guideline on clinical investigation of medical products used in the treatment of osteoarthritis and reflections about related clinically relevant outcomes: expert consensus statement.
Reginster, Jean-Yves; REITER-NIESERT, S.; Bruyère, Olivier et al.
2015In Osteoarthritis and Cartilage, 23, p. 2086-2093
Peer Reviewed verified by ORBi
 

Files


Full Text
Recommendations for an update of the 2010 European regulatory guideline on clinical investigation of medicinal products used in treatment of osteoarthritis and reflections about related clinically relevant outcomes ex.pdf
Publisher postprint (199.63 kB)
Request a copy

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
Osteoarthritis; Registration of drugs; Guideline
Abstract :
[en] Objective: The European Society on Clinical and Economic aspects of Osteoporosis and Osteoarthritis (ESCEO) organised a working group to evaluate the need for updating the current European guideline on clinical investigation of drugs used in the treatment of osteoarthritis (OA). Design: Areas of potential attention were identified and the need for modifications, update or clarification was examined. Proposals were then developed based on literature reviews and through a consensus process. Results: It was agreed that the current guideline overall still reflects the current knowledge in OA, although two possible modifications were identified. The first relates to the number and timing of measurements required as primary endpoints during clinical trials of symptom-relieving drugs, either drugs with rapid onset of action or slow acting drugs. The suggested modifications are intended to take into consideration the time related clinical need and expected time response to these drugs e i.e., a more early effect for the first category in addition to the maintenance of effect, a more continuous benefit over the long-term for the latter e in the timing of assessments. Secondly, values above which a benefit over placebo should be considered clinically relevant were considered. Based on literature reviews, the most consensual values were determined for primary endpoints of both symptom-relieving drugs (i.e., pain intensity on a visual analogue scale (VAS)) and disease-modifying drugs (i.e., radiographic joint-space narrowing).
Disciplines :
General & internal medicine
Author, co-author :
Reginster, Jean-Yves  ;  Université de Liège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
REITER-NIESERT, S.
Bruyère, Olivier  ;  Université de Liège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
BERENBAUM, F.
BRANDI, M.L.
BRANCO, J.
DEVOGELAER, J.P.
HERRERO-BAUMONT, G.
KANIS, J.
MAGGI, S
MAHEU, E.
RICHETTE, P.
RIZZOLI, R.
COOPER, C
More authors (4 more) Less
Language :
English
Title :
Recommendations for an update of the 2010 European regulatory guideline on clinical investigation of medical products used in the treatment of osteoarthritis and reflections about related clinically relevant outcomes: expert consensus statement.
Publication date :
2015
Journal title :
Osteoarthritis and Cartilage
ISSN :
1063-4584
eISSN :
1522-9653
Publisher :
W.B. Saunders, London, United Kingdom
Volume :
23
Pages :
2086-2093
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 22 December 2015

Statistics


Number of views
72 (6 by ULiège)
Number of downloads
1 (1 by ULiège)

Scopus citations®
 
46
Scopus citations®
without self-citations
32
OpenCitations
 
39

Bibliography


Similar publications



Contact ORBi